
Sign up to save your podcasts
Or


Results of this trial indicate that dapagliflozin treatment immediately after an acute heart attack reduced adverse cardiovascular and metabolic outcomes. In this interview, Stefan James MD, PhD and Laxmi Mehta MD, FACC, discuss AHA Late-Breaker: DAPA-MI - A Registry-Based Randomized Trial of Dapagliflozin in Patients With Acute Myocardial Infarction Without Diabetes.
Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL
By American College of Cardiology3.8
5454 ratings
Results of this trial indicate that dapagliflozin treatment immediately after an acute heart attack reduced adverse cardiovascular and metabolic outcomes. In this interview, Stefan James MD, PhD and Laxmi Mehta MD, FACC, discuss AHA Late-Breaker: DAPA-MI - A Registry-Based Randomized Trial of Dapagliflozin in Patients With Acute Myocardial Infarction Without Diabetes.
Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL

136 Listeners

319 Listeners

496 Listeners

170 Listeners

884 Listeners

291 Listeners

140 Listeners

1,159 Listeners

41 Listeners

195 Listeners

90 Listeners

364 Listeners

430 Listeners

369 Listeners

32 Listeners